Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 301 - 325 of 14580 in total

Acetylcysteine

Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Matched Description: … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment …
Matched Mixtures name: … Levomefolate Calcium Acetylcysteine and Mecobalamin Algal ... Levomefolate Calcium, Acetylcysteine, Mecobalamin and Algal …
Matched Categories: … Cough and Cold Preparations ... Amino Acids, Peptides, and Proteins …

Larotrectinib

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Pitolisant

Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and …

Pascopyrum smithii pollen

Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Twenty-Two Standardized and Non-Standardized Grasses …

Benzatropine

Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of...
Approved
Matched Description: … It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the ... [A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500] ... an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and …

Cyclobenzaprine

Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond.[A185039,A184982] Since its approval, it has...
Approved
Matched Description: … Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been …

Melphalan flufenamide

Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved ... which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Tepotinib

Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. ... ] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma. ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ertugliflozin

Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... metformin and ertugliflozin ... sitagliptin and ertugliflozin …

Turoctocog alfa pegol

Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general ... It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Lorazepam

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Bimatoprost

Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Description: … Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. ... the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and ... [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of ... 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization …

Tivozanib

Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Varicella zoster vaccine (live/attenuated)

Live attenuated zoster vaccine is available as two products: Zostavax for the prevention of shingles in immunocompetent people over the age of 50, and Varivax for the prevention of chickenpox in individuals 12 months of age and older. While the two vaccines contain the same immunological components and provide protection...
Approved
Matched Description: … and post-herpetic neuralgia. ... efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in patients ... Varivax for the prevention of chickenpox in individuals 12 months of age and older. …
Matched Mixtures name: … PROQUAD® ( Measles, Mumps, Rubella AND Varicella (Oka/Merck) Virus Vaccine Live, MSD) LYOPHILIZED VACCINE …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved

Formoterol

Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic ... mixture of its active (R;R)- and inactive (S;S)-enantiomers. ... Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was …
Matched Mixtures name: … Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate …
Matched Categories: … formoterol and mometasone ... formoterol and budesonide ... formoterol and fluticasone ... formoterol and beclometasone ... formoterol and aclidinium bromide …

Methionine

A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical
Matched Mixtures name: … Aminosyn II and Dextrose ... Aminosyn II and Dextrose ... Men's Biomultiple Vitamin and Mineral Supplement …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Asparagine

A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Approved
Investigational
Nutraceutical
Matched Description: … (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) ... It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. ... A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Phentermine

Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Description: … Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical ... [A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely …
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …

Ethionamide

A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Approved
Matched Description: … (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) …

Benzphetamine

A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Approved
Illicit

Melphalan

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem...
Approved
Matched Description: … [A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 301 - 325 of 14580 in total